In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Acutaas Chemicals has informed that the Board of Directors of the Company at their meeting held on Friday, October 17, 2025, considered & approved the Unaudited Standalone & Consolidated Financial Results for the second quarter & half year ended on September 30, 2025 along with Balance Sheet and Cash Flow Statement for the half year ended September 30, 2025, as reviewed and recommended by the Audit Committee, and the Limited Review Report issued by Statutory Auditors of the Company, Maheshwari & Co., Chartered Accountants. The Board Meeting commenced at 11.00 am and concluded at 11.50 am.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: